by cnolan
Catalyst Biosciences Inks $7M from Phizer
Posted on: January 6, 2012 by cnolanNo Comments »
Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.
